Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

Table 5

Plasma creatinine, urine creatinine, and creatinine clearence.

(mean ± SD, 𝑛=8)	1st year				2nd year
	Baseline	Week 13	Week 26	Week 52	Washout	Week 13	Week 26	Week 52	𝑃-value*
Treatment	None	GLP-2	GLP-2	GLP-2	None	GLP-2	GLP-2 + Cholyl-sarcosine#	GLP-2
Plasma Creatinine (mmol/l)	0.103±0.019	0.097±0.019§	0.096±0.019§	0.095±0.020 §	0.094±0.023 §	0.088±0.018 §	0.101±0.029 §	0.086±0.024 §	.01
Urine Creatinine (mmol/d)	11±3	13±4	13±4	13±4	8±4	11±3	12±5	13±4	.016
Creatinine Clearence (mL/min)	73±22	91±14 §	97±21 §	93±28 §	67±43	90±26 §	85±36 §	105±23 §	.04

∗Friedman repeated measures analysis of variance on ranks in patients completing the study. For comparisons of admission periods to the baseline period, the Dunnett method was used as the post hoc test. § ~ P<.05. #Cholylsarcosine was given two days prior to the admission and during the 72-hour balance studies.